Six products, four of them buyable
The weight-loss page prices a semaglutide tablet, a compounded semaglutide injection, a compounded tirzepatide and a tirzepatide tablet, then lists two brand-name injections with cash figures and a coming-soon label.
Publishing a cash figure for a brand product it does not yet sell is unusual. The figures are large and the labels are clear, so nothing is disguised, but neither is a price a reader can act on.
Twenty-seven of the one hundred and fifty-eight sellers here price an oral route. This is one of the few that prices an oral for each molecule.
Two listings, one description
The listing called Compounded Tirzepatide and the listing called Tirzepatide Tablets carry the same figure and the same description: the same active ingredient as two named brands, taken sublingually once a day.
One of those names implies an injection and one implies a tablet, and the seller's own copy describes both as a daily sublingual. Our record carries one as an injection and one as an oral, on the strength of the product names, and this paragraph exists because the descriptions do not support that split.
Ask which of the two is which before ordering. The distinction is a route of administration, not a packaging detail.
The banner and the page disagree
A site-wide banner that renders on the privacy policy advertises a starting figure noticeably above the lowest figure on the product page. Both are the seller's own words on the seller's own site, and neither is marked as superseding the other.
The privacy policy names the operating limited liability company in its first sentence, which is clean. No compounding pharmacy is named, no individual clinician is named, and no service area is published.
The compounded-medication disclaimer sits on the priced page itself rather than in a policy document, which is where it belongs.
Remote Pharmacy's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $167/moas low as; the site-wide banner on the same site says "Get started for as little as $287/month", which is a hundred and twenty dollars higher than this page | September 2026source |
| Semaglutide (compounded-oral) | $167/moas low as, for the tablet, the same figure as the injection of the same drug | September 2026source |
| Tirzepatide (compounded) | $229.99/moas low as, for the product listed as Compounded Tirzepatide; the seller's own description of it reads "taken sublingually once a day", which does not match the injectable framing of the listing beside it | September 2026source |
| Tirzepatide (compounded-oral) | $229.99/mostarts at, for the separately listed Tirzepatide Tablets - the same figure and the same description as the listing above it | September 2026source |
| Semaglutide (brand) | $1,319/mostarts at, and the listing is marked Coming Soon - a published price for something the seller says it does not yet sell | September 2026source |
| Semaglutide (brand) | $1,672/mostarts at, also marked Coming Soon | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Remote Pharmacy's current price →Good fit if
- Buyers who want a daily tablet priced beside a weekly injection from the same seller.
- Readers who want a cash figure for a brand product for comparison, even one not yet on sale.
- People who want the compounded disclaimer on the page carrying the prices.
Look elsewhere if
- Anyone who needs to know whether a product is an injection or a sublingual; two listings share one description.
- Buyers who want the banner and the product page to agree.
- Readers who need the pharmacy named or a service area published.
- People who want the brand products now rather than when the labels come off.
How this review was verified
- Read the weight-loss page and the privacy policy on 6 September 2026, with a nonsense-path control on the host in the same run.
- Recorded the description attached to each listing rather than inferring the route from the product name, which is how the contradiction between the two tirzepatide listings was found.
- Compared the site-wide banner figure against the product page figure and recorded both, on the surfaces that carry them.
- Recorded the two brand figures with their coming-soon labels rather than as available prices.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.